



- 333 National Arthritis Month May 2001
- 334 Prevalence of Arthritis United States, 1997
- 337 Trends in Blood Lead Levels Among Children — Boston, Massachusetts, 1994–1999
- 340 National Estimates of Nonfatal Injuries Treated in Hospital Emergency Departments — United States, 2000

National Arthritis Month — May 2001

May is National Arthritis Month. Arthritis and other rheumatic conditions are the leading cause of disability in the United States, affecting approximately 43 million persons in 1997, and may affect 60 million by 2020 (1,2). Early symptom recognition is needed to achieve better control of arthritis. CDC, the Arthritis Foundation, and other organizations continue to implement the *National Arthritis Action Plan: A Public Health Strategy* (3) to promote progress toward reaching the arthritis-related national health objectives for 2010 (4).

Additional information about arthritis, National Arthritis Month, Arthritis Action Day, the National Arthritis Action Plan, and local Arthritis Foundation programs and services is available from the Arthritis Foundation, telephone (800) 283-7800, or at http://www.arthritis.org.*

- 1. CDC. Prevalence of disabilities and associated health conditions among adults—United States, 1999. MMWR 2001;50:120–5.
- 2. CDC. Arthritis prevalence and activity limitations—United States, 1990. MMWR 1994:43:433–8.
- 3. Arthritis Foundation, Association of State and Territorial Health Officials, and CDC. National arthritis action plan: a public health strategy. Atlanta, Georgia: Arthritis Foundation, 1999.
- 4. US Department of Health and Human Services. Healthy people 2010 (conference ed., 2 vols). Washington, DC: US Department of Health and Human Services, 2000.

^{*}References to sites of nonfederal organizations on the World-Wide Web are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

Prevalence of Arthritis — United States, 1997

Arthritis and other rheumatic conditions (i.e., arthritis) are among the most prevalent diseases in the United States (1) and the most frequent cause of disability (2). In 1985, an estimated 35 million persons were affected by arthritis (3); in 1990 (1), a study using a broader arthritis definition estimated that 38 million were affected. To better characterize these conditions, CDC analyzed a variety of data for 1997 using common definitions from the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM). The findings of one such analysis in the National Health Interview Survey (NHIS) indicated that, in 1997, the prevalence of persons with arthritis had increased by approximately 750,000 per year since 1990. Findings also support earlier projections that by 2020, 60 million persons may be affected by arthritis and that the activities of 11.6 million persons may be limited by arthritis (1). More widespread implementation of existing interventions may reduce the occurrence and progression of arthritis.

Prevalence rates were estimated from NHIS, a probability sample of the civilian, noninstitutionalized population in the United States (1). Data from the 1994–1995 NHIS, the most recent surveys using ICD-9 codes for health conditions, were used to estimate the 1997 prevalence and physical activity limitations from arthritis. Estimates of arthritis prevalence rates were derived from a random sample of 36,057 (16.7%) of 218,646 respondents who were asked about the presence during the 12 months preceding the survey of any of various musculoskeletal conditions and for details of these conditions. Each condition reported was assigned an ICD-9 code. Respondents with one or more codes recommended by the National Arthritis Data Workgroup (NADW) to represent arthritis* (1) were included in the analysis. Estimated rates of activity limitations attributed to arthritis were based on responses from 218,646 respondents who were asked whether they were limited in or prevented from working, housekeeping, or performing other activities as a result of a health condition(s) and, if so, did they attribute the limitation to arthritis.

To determine the number of persons affected or limited by arthritis, age- and sex-specific prevalence rates were calculated for the civilian, noninstitutionalized population, the referent population for NHIS, and were applied to the estimated 1997 U.S. population (4) by age and sex. Rates of disease burden for the total population were generated by totaling the age- and sex-specific estimates; 95% confidence intervals were calculated using SUDAAN to account for NHIS's complex survey design.

Results of these analyses indicated that an estimated 43 million persons had arthritis in 1997. All age groups were affected, including the working-age population, and rates increased with age. Females had higher arthritis rates than males overall and for each age group (Table 1). An estimated eight million persons (3% of the U.S. population) reported arthritis as a major or contributing cause of activity limitations (Table 1). Rates increased with age and females had higher rates of activity limitations than males overall and for each age group (Table 1).

Reported by: Health Care and Aging Studies Br, Div of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

^{*}Codes 95.6, 95.7, 98.5, 99.3, 136.1, 274, 277.2, 287.0, 344.6, 353.0, 354.0, 355.5, 357.1, 390, 391, 437.4, 443, 446, 447.6, 696.0, 710–716, 719.0, 719.2–719.9, 720–721, 725–727, 728.0–728.3, 728.6–728.9, 729.0–729.1, and 729.4.

Arthritis — Continued

TABLE 1. Estimated prevalence of self-reported arthritis and activity limitations attributed to self-reported arthritis, by sex and age — United States, 1997

	Person	s with art	hritis	Persons with activity limitations caused by arthritis					
Sex/Age	No.*	Rate⁺	(95% CI [§])	No.	Rate	(95% CI)			
Male [¶]	16,367	12.5	(±1.3)	2,385	1.8	(±0.2)			
<u><</u> 24	400	0.8	(±0.2)	46	0.1	(± 0.0)			
25-34	1,080	5.5	(±1.0)	97	0.5	(± 0.1)			
35-44	2,303	10.5	(±1.2)	289	1.3	(± 0.2)			
45-54	3,190	19.4	(±1.9)	340	2.1	(± 0.3)			
55-64	3,081	29.7	(± 2.4)	537	5.2	(+0.6)			
65–74	3,684	44.5	(±3.0)	588	7.1	(± 0.7)			
75–84	2,154	46.4	(± 4.3)	371	8.0	(±1.0)			
<u>≥</u> 85	477	42.1	(±8.7)	116	10.3	(± 2.3)			
Female	26,777	19.5	(±1.5)	5,502	4.0	(± 0.3)			
<u><</u> 24	696	1.5	(± 0.3)	69	0.2	(± 0.0)			
25-34	1,708	8.6	(± 1.0)	210	1.1	(± 0.2)			
35-44	3,487	15.7	(±1.6)	482	2.2	(± 0.2)			
45-54	4,761	27.7	(±2.1)	848	4.9	(± 0.4)			
55-64	4,676	40.9	(± 2.6)	1,076	9.4	(± 0.6)			
65–74	5,348	52.2	(± 2.6)	1,183	11.6	(± 0.8)			
75–84	4,339	61.1	(±3.0)	1,074	15.1	(± 1.0)			
≥85	1,762	63.3	(±5.9)	559	20.1	(± 2.3)			
Total	43,147	16.1	(±1.4)	7,887	2.9	(±0.3)			

^{*} In thousands. To generate national estimates, 1994–1995 NHIS-estimated age- and sexspecific rates of the civilian, noninstitutionalized population were applied to the estimated 1997 U.S. population of that age and sex.

Editorial Note: The findings in this report indicate that from 1990 to 1997, the prevalence of persons with arthritis and with activity limitations from arthritis increased substantially. Related analyses have documented 744,000 hospitalizations and 44 million ambulatorycare visits for arthritis in 1997 (5).

NADW's definition of arthritis aims to include specific conditions that would be understood as arthritis (e.g., systemic lupus erythematosus, infectious arthritis, and carpal tunnel syndrome). Because many persons with arthritis may not consult a physician for their condition (6), NHIS self-reported data may provide a more accurate estimate of the prevalence and impact of arthritis than medical encounter-based data. In addition, the data allow an understanding of the time trends in arthritis because the case definitions and survey methods are the same as the 1990 estimates (1).

The findings in this study are subject to at least four limitations. First, the estimates used self-reported data that were not confirmed by a physician. Second, to estimate the total burden of disease, the analysis used rates based on surveys of the civilian, noninstitutionalized population, which represents 98% of the total U.S. population but excluded certain groups (e.g., the institutionalized elderly) that are likely to have different

[†] Per 100 persons.

[§] Confidence interval.

¹ Male, female, and total population cases and rates estimated from totaling age- and sex-specific cells. Cls estimated using age- and sex-specific rates to calculate lower and upper ranges of age- and sex-specific cases, totaling, and then dividing by estimated population. Source: 1994–1995 National Health Interview Survey.

Arthritis — Continued

rates. Third, data used intercensal projections for denominators; these projected denominators may be inaccurate. Finally, rate estimates were assumed unchanged from 1995 to 1997; however, this may be reasonable because age- and sexspecific prevalence rates were virtually unchanged from 1990 (1).

Further studies are needed to define the prevalence of specific types of arthritis, to provide direct measures of arthritis prevalence, to determine the financial and societal impact of arthritis, and to quantify the impact of arthritis at the state level and in health-care systems. Future analyses of NHIS data will need to accommodate the change from ICD-9-based code assignment of conditions to a symptom-based approach to the case definition of arthritis.

Interventions are available that may reduce the occurrence and progression of arthritis. Measures to reduce obesity and avoid occupational and sports injuries can be expected to reduce the risk for osteoarthritis of the knees (7). Other interventions include supervised exercise programs, weight loss, and self-education courses such as the Arthritis Self-Help Course, which has been shown to reduce pain and physician visits (8). Unless such interventions are implemented quickly and widely, national projections suggest that arthritis will become a larger public health problem (1). Health-care providers, policymakers, and the public health community need to plan for the impact of this growth. CDC funds 37 state health departments to develop or enhance prevention programs and to identify new approaches to improving the quality of life for persons affected by arthritis (9).

- 1. CDC. Arthritis prevalence and activity limitations—United States, 1990. MMWR 1994;43:433-8.
- 2. CDC. Prevalence of disabilities and associated health conditions among adults—United States, 1999. MMWR 2001;50:120–5.
- 3. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16:427–41.
- 4. Population Division, US Census Bureau. Resident population estimates of the U.S. by age and sex: April 1, 1990 to July 1, 1999. Available at http://www.census.gov/population/estimates/nation/intfile2-1.txt. Accessed November 29, 2000.
- 5. CDC. Impact of arthritis and other rheumatic conditions on the health-care system—United States, 1997. MMWR 1999;48:349–53.
- 6. Rao JK, Callahan LF, Helmick CG. Characteristics of persons with self-reported arthritis and other rheumatic conditions who do not see a doctor. J Rheumatol 1997;24:169–73.
- 7. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women, the Framingham study. Ann Intern Med 1992;116:535–9.
- 8. Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum 1993;36:439–46.
- Arthritis Foundation, Association of State and Territorial Health Officials, and CDC. National arthritis action plan: a public health strategy. Atlanta, Georgia: Arthritis Foundation, 1999.

Trends in Blood Lead Levels Among Children — Boston, Massachusetts, 1994–1999

Data from the National Health and Nutrition Examination Survey and national childhood blood lead surveillance data from 19 states indicated that average blood lead levels (BLLs) in young children decreased during the late 1990s (1–3). The proportion of children tested who had BLLs \geq 10 μ g/dL declined from 10.5% in 1996 to 7.6% in 1998, although the proportion was higher in certain counties (3). To determine whether a similar decline had occurred in Boston, Massachusetts, where a high proportion of children are tested each year, and whether any changes were similar in high- and low-risk neighborhoods, CDC, in collaboration with the Boston Childhood Lead Poisoning Prevention Program (BCLPPP) performed an analysis of BLLs among children aged 6–72 months in Boston during 1994–1999. The results indicate that BLLs in Boston declined during this period, but because of the geographic variation in lead exposure, continued surveillance will be necessary to eliminate childhood lead poisoning.

Private laboratories are mandated by Massachusetts law to report all blood lead test results to the state laboratory. BCLPPP receives all blood lead test results for Boston residents from the state laboratory. Massachusetts lead screening regulations require that health-care providers screen children at age 9–12 months and annually up to age 48 months. Children at high risk for lead poisoning are screened every 6 months during ages 6 months-3 years and annually from ages 3-6 years. The proportion of children tested who had BLLs \geq 10 μ g/dL and \geq 20 μ g/dL by fiscal year (FY) from July 1, 1993, through June 30, 1999, was computed. Children were counted once in each FY in which they had at least one blood lead test, and the highest test result in a given FY was considered in the analysis. Because sample contamination of a capillary test can result in a slight overestimation of BLLs, only tests performed on venous samples with BLLs \geq 10 μ g/dL were considered in the numerator, and tests using both venous and capillary samples were used in the denominator (4,5). Massachusetts Institute for Social and Economic Research data were used to estimate the population of children aged <6 years for 1994 and 1998 (4). U.S. census data from 1990 were used to characterize 16 Boston neighborhoods by ZIP code according to factors that may indicate risk for lead exposure (e.g., percentage of pre-1950 housing, minority children, and children aged <6 years living in poverty). Housing parcel information was obtained from tax assessor data.

The number of children aged 6–72 months screened annually in Boston declined 23%, from 35,304 (73.3% of the population aged <6 years) in 1994 to 27,233 (61.6% of population aged <6 years) in 1999 (Figure 1). However, screening among children aged 9–48 months remained high (82% during FY 1999).

During 1994–1999, the overall prevalence of children with BLLs \geq 10 μ g/dL declined 45%, from 9.3% (3265) to 5.1% (1398). The prevalence of children with BLLs \geq 20 μ g/dL declined 66%, from 1.5% (545) to 0.5% (140) (Figure 1). Neighborhoods with prevalence rates in the upper tertile in 1994 had a higher percentage of children living in poverty, Spanish-speaking households, and vacant parcels than neighborhoods with lower prevalence rates (Table 1). Overall, about two thirds of houses were built before 1950, and no substantial differences were found in the proportion of houses built before 1950 between the highest and lowest risk neighborhoods. The prevalence of elevated BLLs declined from 1994 to 1999 in all 16 neighborhoods, with the highest absolute average decline

Blood Lead Levels — Continued

FIGURE 1. Number of children tested for blood lead and prevalence of these children with elevated blood lead levels (BLLs), by year — Boston, Massachusetts, 1994–1999




TABLE 1. Risk levels for elevated blood lead levels (BLLs) in 16 neighborhoods, by risk factor — Boston, Massachusetts, 1994–1999

Neighborhood prevalence tertile*		lence	Absolute change in average prevalence of BLLs ≥10 µg/dL 1994–1999	% children aged <6 years with BLLs ≥10 µg/dL 1999	Average % children aged <6 years living below poverty level	Average % pre-1950 housing	% vacant parcels	% minorities	Average % Spanish- speaking households
							•		
High	11.0	6.2	4.8	79.8%	31.1%	67.6%	63.0%	21.0%	12.1%
Medium	5.5	3.0	1.5	18.6%	24.8%	65.2%	25.0%	9.4%	8.4%
Low	2.5	1.2	1.3	1.6%	22.5%	66.2%	12.0%	3.5%	4.4%

^{*} Neighborhood risk was based on the 1999 average prevalence of BLLs ≥10µg/dL in 16 neighborhoods.

(4.8%) in neighborhoods with the highest prevalence in 1994. In 1999, six high-risk neighborhoods accounted for 80% of children with elevated BLLs, approximately the same as in 1994 (83%).

The decline in prevalence of elevated BLLs during 1994–1999 was similar across age groups: 51% among children aged <12 months, 42% among children aged 12–36 months, and 46% among children aged 36–72 months.

Reported by: S Franco, MS, Childhood Lead Poisoning Prevention Program, Boston Public Health Commission, Boston, Massachusetts. Lead Poisoning Prevention Br, Div of Environmental Hazards and Health Effects, National Center for Environmental Health, CDC.

Blood Lead Levels — Continued

Editorial Note: The findings in this report indicate that the prevalence of elevated BLLs in Boston declined consistently during 1994–1999, similar to declines reported from 19 states (3). Building of new houses and remodeling of older houses that removed lead painted building components, such as windows, may have contributed to this decrease (6). In addition, under the Massachusetts Lead Law*, BCLPPP has required property owners to correct lead paint hazards in dwellings occupied by children aged <6 years. Since 1985, approximately 6800 de-leading code enforcement activities have occurred in Boston, and the law has encouraged many additional property owners to comply with de-leading activities (BCLPPP, unpublished data, 2000).

Although BLLs have declined in all Boston neighborhoods, levels remained higher in 1999 in the areas with the highest levels in 1994. These high-risk neighborhoods are characterized by higher proportions of minority children, children living in poverty, and vacant properties; a high proportion of old housing, likely to have leaded paint, is found in all neighborhoods. Low socioeconomic status and associated deterioration of older housing are major contributors to lead exposure in Boston (7).

The findings in this report are subject to at least four limitations. First, reporting of blood lead test results varied among different laboratories; therefore, results may not be uniform. Second, children at high risk for blood lead poisoning also may have high screening rates. Third, this analysis does not include lead exposure measures associated with the children in the study; as a result, the prevalence rates in the population screened may not be representative of all children in Boston. Finally, the use of older housing and demographic information (i.e., census and tax assessor data) may not reflect changes in some Boston neighborhoods.

Approximately 1300 children in Boston are identified annually with BLLs \geq 10 μ g/dL, levels high enough to adversely affect cognitive development and behavior. One of the national health objectives for 2010 is to eliminate childhood lead poisoning (8). Because of the substantial geographic variation in lead exposure, continued use of blood lead data for surveillance purposes will be essential in Boston and other jurisdictions to focus resources on high-risk neighborhoods and to achieve the health objective.

- 1. CDC. Blood lead levels—United States, 1988-1991. MMWR 1994;43:545-8.
- 2. CDC. Update: blood lead levels—United States, 1991-1994. MMWR 1997;46:141-6.
- 3. CDC. Blood lead levels in young children—United States and selected states, 1996–1999. MMWR 2000;49:1133–7.
- 4. CDC. Preventing lead poisoning in young children. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1991.
- 5. CDC. Screening young children for lead poisoning: guidance for state and public health officials. Atlanta, Georgia: US Department of Health and Human Services, CDC, 1997.
- Public Health Service. Strategic plan for the elimination of childhood lead poisoning.
 Washington, DC: US Department of Health and Human Services, Public Health Service, 1991.
- 7. Clark CS, Bornschein RL, Succop P, Que Hee SS, Hammond PB, Peace B. Condition and type of housing as an indicator of potential environmental lead exposure and pediatric blood lead levels. Environ Res 1985;38:46–53.
- 8. US Department of Health and Human Services. Healthy people 2010 (conference ed, 2 vols). Washington, DC: US Department of Health and Human Services, 2000.

^{*105} Code of Massachusetts Regulations 460.700.

National Estimates of Nonfatal Injuries Treated in Hospital Emergency Departments — United States, 2000

On July 1, 2000, the Consumer Product Safety Commission's (CPSC) National Electronic Injury Surveillance System (NEISS) was expanded to collect data on all types and external causes of nonfatal injuries and poisonings treated in U.S. hospital emergency departments (EDs). This augmented system, called NEISS All Injury Program (NEISS-AIP), is a collaborative effort between CDC's National Center for Injury Prevention and Control and CPSC. This report presents annualized national estimates using NEISS-AIP data obtained during July 1–September 30, 2000, which indicate that approximately 31,000,000 persons were treated for nonfatal injuries in EDs in 2000. Although most of the injuries were unintentional, an estimated 1,973,000 were violence-related. Data from NEISS-AIP can be used for monitoring temporal trends in nonfatal injuries by mechanism and intent of injury.

NEISS-AIP data were collected from 66 of the 100 NEISS hospitals, which were selected as a stratified probability sample of all hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED (1,2). The 66 NEISS-AIP hospitals are a nationally representative sample of U.S. hospital EDs. NEISS-AIP hospitals provide data on approximately 600,000 injury- and consumer product-related ED cases each year. Data from these cases are weighted by the inverse of the probability of selection to provide national estimates (1). Annualized estimates were based on weighted data for 126,547 nonfatal injury-related ED visits during July 1–September 30, 2000. Each sample was weighted by four and then these adjusted weights were added to provide annualized estimates for the overall population and population subgroups (i.e., age, sex, and race/ethnicity*). SUDAAN was used to account for the complex sample design (1).

Nonfatal injuries and poisonings were defined as bodily harm resulting from acute exposure to an external force or substance (i.e., mechanical, thermal, electrical, chemical, or radiant) and near drowning, including unintentional and violence-related causes. Cases were excluded if 1) the principal diagnosis was an illness, pain only, psychological harm (e.g., anxiety and depression) only, contact dermatitis associated with exposure to consumer products (e.g., body lotions, detergents, and diapers) and plants (e.g., poison ivy), or unknown; or 2) the ED visit was for adverse effects of therapeutic drugs or of surgical and medical care (3).

All injuries were classified for intent of injury (i.e., unintentional, assault, self harm, and legal intervention) and mechanism of injury (i.e., fall, struck by/against, motor-vehicle-occupant-related incident, cut/pierce, and fire/burn) (4). Unintentional included unintended injuries and injuries in which no indication of intent to harm was documented in the ED record. Assault included suspected and confirmed injuries from interpersonal violent events (e.g., injuries to victims, innocent bystanders, police, and perpetrators). Self harm included suspected and confirmed intentionally self-inflicted injuries. Legal intervention included injuries inflicted by police or other legal authorities (e.g., security guards) while acting in the line of duty. The mechanism of injury represents the precipitating mechanism that initiated the chain of events leading to the injury, which is similar

^{*}On the ED record, often only one entry is available for race or ethnicity. The classification scheme for this report assumed that most white Hispanics probably were recorded on the ED record as Hispanics and most black Hispanics probably were recorded as black.

Nonfatal Injuries — Continued

to the underlying cause for injury-related death. Mechanisms of injury were classified by trained coders into recommended major external cause-of-injury groupings (3,5) using definitions consistent with *International Classification of Diseases, Ninth Revision, Clinical Modifications* (ICD-9-CM) external cause coding guidelines (6). Because of limited resources, ICD-9-CM external cause-of-injury codes were not assigned.

During 2000, persons with nonfatal injuries were treated in EDs at an estimated rate of 11,188 per 100,000 population. The nonfatal injury rate was approximately 40% higher for males than for females (Table 1). Males aged 15–19 years had the highest nonfatal injury rate (20,528 per 100,000 population) (Table 1). Of the estimated 31,000,000 nonfatal injuries, 93.6% were unintentional and the remaining 6.4% were violence-related, including assaults (5.5%), intentional self harm (0.7%), and legal interventions (0.2%) (Table 2). Falls were the leading cause of unintentional nonfatal injuries, accounting for an estimated 7,021,000 (24.4%) of unintentional injury-related ED visits. An estimated 3,299,000 persons were injured as an occupant in a motor vehicle (Table 2), of which 95.2% were traffic-related. Injuries to motor-vehicle occupants were the leading cause of unintentional nonfatal injury-related ED visits for females aged 15–24 years. The nonfatal injury rate for pedal cyclists was 2.9 times higher for males than for females (Table 2). An estimated 389,000 persons were treated in EDs for dog bites (Table 2).

Of an estimated 1,973,000 violence-related nonfatal injuries, 66% were physical assaults that included being hit with an object or by another person (Table 2). Sexual assault was the fourth leading cause of violence-related, nonfatal injury-related ED visits; the nonfatal rate of sexual assault for females was 4.8 times higher than that for males (Table 2). Approximately 150,000 persons were treated in EDs for poisoning-related suicide attempts and the rate of intentionally self-inflicted, nonfatal poisonings for females was 1.6 times that for males (Table 2).

Reported by: Office of Statistics and Programming, National Center for Injury Prevention and Control, CDC.

Editorial Note: The findings in this report indicate that, in 2000, approximately 10% of U.S. residents were treated for nonfatal injuries in EDs. On the basis of NEISS-AIP and National Vital Statistics System data (7), for every injury-related death in the United States, approximately 200 persons were treated for nonfatal injuries in EDs. Most (93.6%) of these injuries were unintentional; however, approximately 2 million persons were treated for violence-related injuries. NEISS-AIP will provide a national data source for further characterizing these injuries by unintentional and violence-related causes and helping to identify those at risk.

NEISS-AIP will provide additional data on the characteristics and circumstances of injuries that are treated in EDs. In addition to age, race/ethnicity, sex, intent of injury, and mechanism of injury, data are being collected on principal diagnosis, primary body part affected, locale where the injury occurred, work-relatedness, consumer products involved, and disposition at ED discharge. For transport-related injuries, data are being collected on traffic-relatedness and on motor-vehicle occupant status (e.g., driver, passenger, boarding, and alighting) at the time of the injury. For assaults, data are being collected on the relationship of the perpetrator to the injured person (e.g., spouse/partner, parent, other relative, friend, and stranger) and the context (e.g., altercation, robbery, sexual assault, drug-related, and gang-related). In addition, on the basis of information in the ED record, a brief narrative is being recorded that provides further details about the circumstances of the incident.

Nonfatal Injuries — Continued

Annualized national estimates of NEISS-AIP data for July 1-September 30, 2000, are comparable to estimates based on other surveys. Data for 1998 from the National Hospital Ambulatory Medical Care Survey (NHAMCS), which collects data on all types of ED visits and focuses primarily on health-care utilization, identified an average annual estimate of 37,111,000 injury-related ED visits (8). NHAMCS used an injury definition similar to that of NEISS AIP. However, the NHAMCS estimate includes both initial ED visits and revisits for the same injury; the NEISS-AIP estimate includes only initial ED visits. Data from a 3-month NEISS All Injury Pilot Study conducted during May 1–July 31, 1997, of a nationally representative sample of 21 NEISS hospitals identified an annualized estimate of 29,060,000 injuries (9). The distributions of injuries by intent and mechanism of injury were similar among all three data sources. For example, the percentage of injury-related ED visits that were violence-related was 5.2% for NHAMCS, 5.6% for the NEISS All Injury Pilot Study, and 6.4% for NEISS-AIP. The percentage of violence-related cases for NEISS-AIP might be expected to be highest because data were obtained for ED visits during July–September when assault rates are higher than during other months of the year (10).

The findings in this report are subject to at least three limitations. First, this system provides only national estimates and does not allow for estimates by region, state, or local jurisdiction. Second, data are based solely on information provided in the ED record and are not linked to criminal justice, police reports, or other data sources to supplement or verify the cause and intent of injury. Finally, because the estimates were derived from 3 months of data, they do not account for cause-specific seasonal differences in the number of injuries (10).

Hospital audits conducted by CPSC indicate that NEISS hospital coders identify approximately 90% of all reportable product-related cases (A. McDonald, CPSC, personal communication, 2001). NEISS also has the capacity to conduct special studies to collect more details about specific types and causes of injury, and in-depth follow-up interviews for case studies of injury circumstances and consumer product involvement.

- 1. US Consumer Product Safety Commission. The NEISS sample: design and implementation. In: Kessler E, Schroeder T, eds. Washington, DC: US Consumer Product Safety Commission, 2000.
- 2. US Consumer Product Safety Commission. NEISS coding manual 2000. Washington, DC: US Consumer Product Safety Commission, 2000.
- 3. CDC. Recommended framework for presenting injury mortality data. MMWR 1997;46(no. RR-14).
- 4. CDC. A training module for coding mechanism and intent of injury for the NEISS All Injury Program. In: Annest JL, Pogostin CL, eds. Atlanta, Georgia: US Department of Health and Human Services, CDC, National Center for Injury Prevention and Control, 2000.
- 5. Annest JL, Pogostin CL. CDC's short version of the ICECI (International Classification of External Causes of Injury): a pilot study. Report to the World Health Organization Collaborating Centers on the Classification of Disease. Atlanta, Georgia: US Department of Health and Human Services, CDC, National Center for Injury Prevention and Control, 2000.
- 6. US Department of Health and Human Services. Generic ICD-9-CM. Hospital version 1999. Reno, Nevada: Channel Publishing LTD, 1998.
- 7. Murphy SL. Deaths: final data for 1998. Natl Vital Stat Rep 2000;48:1-105.
- 8. McCaig LF. National Hospital Ambulatory Medical Care Survey: 1998 emergency department summary. Advance data from vital and health statistics; no. 313. Hyattsville, Maryland: US Department of Health and Human Services, CDC, National Center for Health Statistics, 2000.

			Male				Female			Bo	th sexes	*
Characteristic	No.	% [†]	Rate⁵	(95% CI [¶])	No.	%	Rate	(95% CI)	No.	%	Rate	(95% CI)
Age group (yrs)												
0–4	1,509,016	8.6	15,582	(12,851-18,313)	1,076,466	8.2	11,671	(9,856– 13,485)	2,587,021	8.4	13,682	(11,425-15,940)
5–9	1,444,411	8.2	14,162	(11,844-16,480)	966,869	7.3	9,966	(8,460- 11,472)	2,411,708	7.8	12,119	(10,222-14,015)
10–14	1,722,428	9.8	16,738	(14,268-19,209)	973,302	7.4	9,941	(8,521– 11,360)	2,696,014	8.8	13,425	(11,501–15,350)
15–19	2,078,167	11.9	20,528	(17,772-23,284)	1,248,809	9.5	12,962	(11,044-14,879)	3,327,434	10.8	16,841	(14,565-19,117)
20–24	1,880,497	10.7	20,451	(17,085-23,817)	1,190,749	9.0	13,281	(11,242-15,319)	3,071,245	10.0	16,911	(14,284-19,538)
25–34	3,065,461	17.5	16,427	(14,233-18,622)	2,033,962	15.4	10,845	(9,500- 12,190)	5,099,967	16.6	13,630	(11,897-15,364)
35–44	2,646,100	15.1	11,927	(10,420-13,433)	1,953,457	14.8	8,691	(7,679- 9,704)	4,600,868	15.0	10,302	(9,081– 11,522)
45–54	1,508,207	8.6	8,318	(7,293– 9,343)	1,352,626	10.2	7,148	(6,323-7,974)	2,861,165	9.3	7,722	(6,817-8,626)
55–64	728,385	4.2	6,353	(5,519– 7,187)	713,436	5.4	5,697	(4,938- 6,456)	1,441,821	4.7	6,011	(5,232- 6,790)
65–74	449,200	2.6	5,426	(4,546– 6,305)	595,003	4.5	5,963	(5,060- 6,866)	1,044,627	3.4	5,722	(4,879-6,564)
75–84	347,636	2.0	7,084	(5,876– 8,292)	653,379	4.9	8,791	(7,252– 10,329)	1,001,015	3.3	8,112	(6,746–9,478)
≥85	153,255	0.9	12,615	(9,825–15,406)	443,077	3.4	14,415	(11,379–17,451)	596,565	1.9	13,911	(11,038–16,784)
Unknown	4,389	0.0	_	_	2,284	0.0	_	_	7,135	0.0		_
Race/Ethnicity**												
White,												
non-Hispanic	9,852,505	56.2	_	_	7,430,883	56.3	_	_	17,285,964	56.2	_	_
Black	2,548,498	14.5	_	_	2,144,643	16.2	_	_	4,693,939	15.3	_	_
Hispanic	1,361,627	7.8	_	_	791,211	6.0	_	_	2,152,838	7.0	_	_
Other,												
non-Hispanic	500,451	2.9	_	_	406,156	3.1	_	_	907,035	3.0	_	_
Unknown	3,274,071	18.7	_	_	2,430,525	18.4	_	_	5,706,809	18.6	_	_
Total	17,537,152	100.0	13,054	(11,453-14,656)	13,203,419	100.0	9,399	(8,321- 10,477)	30,746,586	100.0	11,188	(9,875- 12,501)

^{*} Includes weighted data for persons of unknown sex.

† Percentages may not total 100% because of rounding.

§ Per 100,000 population.

[¶] Confidence interval.

^{**} Black includes Hispanic and non-Hispanic; Hispanic excludes black Hispanic. Rates are not presented because of the relatively high percentage of unknowns.

			Male					F	emale					Bot	h sexes*	*		
Intent/Mechanism	* No.	% [†]	Rate⁵		(95% (CI ¹)	No.	%	Rate		(95%	CI)	No.	%	Rate		(95%	CI)
UNINTENTIONAL																		
Fall	3,323,673	19.0	2,474	(2	,169–	2,779)	3,696,934	28.0	2,632	(:	2,320-	2,944)	7,021,456	22.8	2,555	(2	,256–	2,854)
Struck by/																		
against	3,590,362	20.5	2,673	(2	,310–	3,036)	1,972,864	14.9	1,404	('	1,235–	1,574)	5,565,289	18.1	2,025	(1	,767–	2,283)
Transport-related	1 2,964,384	16.9	2,207	(1	,855–	2,558)	2,386,488	18.1	1,699	('	1,399–	1,999)	5,352,798	17.4	1,948	(1	,627–	2,269)
Motor-vehicle																		
occupant	1,561,790	8.9	1,163	(932-	1,393)	1,736,193	13.1	1,236	(980-	1,492)	3,298,869	10.7	1,200	(959-	1,441)
Motorcyclist	228,499	1.3	170	(128-	212)	37,638	0.3	27	(18–	36)	266,598	0.9	97	(73-	121)
Pedal cyclist	708,774	4.0	528	(419-	636)	258,031	2.0	184	(150-	217)	967,382	3.1	352	(285-	419)
Pedestrian	108,914	0.6	81	(61–	101)	67,306	0.5	48	(36-	59)	176,220	0.6	64	(49-	79)
Other transpor	rt 356,409	2.0	265	(222-	309)	287,320	2.2	205	(169-	240)	643,729	2.1	234	(197–	271)
Overexertion	1,782,534	10.2	1,327	(1	,122–	1,532)	1,461,168	11.1	1,040	(874-	1,206)	3,243,702	10.5	1,180	(999–	1,361)
Cut/pierce/stab	1,585,313	9.0	1,180	(1	,007–	1,353)	842,484	6.4	600	(514-	685)	2,428,021	7.9	884	(758-	1,009)
Other bite/sting	760,423	4.3	566	(475-	657)	755,387	5.7	538	(457-	618)	1,515,810	4.9	552	(471-	632)
Foreign body	480,180	2.7	357	(300-	415)	271,336	2.1	193	(163-	224)	751,516	2.4	273	(233-	314)
Fire/burn	316,218	1.8	235	(200-	271)	246,804	1.9	176	(148-	203)	563,022	1.8	205	(175-	235)
Dog bite	220,775	1.3	164	(134-	195)	167,949	1.3	120	(95–	144)	388,724	1.3	141	(115-	168)
Machinery	279,570	1.6	208	(166-	250)	52,413	0.4	37	(27-	48)	331,983	1.1	121	(96-	145)
Poisoning	164,480	0.9	122	(91–	154)	120,203	0.9	86	(66–	105)	284,683	0.9	104	(79–	128)
Natural																		
environmental	62,650	0.4	47	(14-	79)	27,864	0.2	20	(9–	31)	90,514	0.3	33	(14-	52)
Inhalation/																		
suffocation	14,663	0.1	11	•	8–	14)	16,883	0.1	12	(7–	17)	31,546	0.1	11	(8–	15)
BB/pellet gunsho	ot 15,831	0.1	12	(8–	15)	2,787††		^{††}		_		18,651	0.1	7	(5–	9)
Firearm gunshot	14,907	0.1	11	(6–	16)	1,919††	$0.0^{\dagger\dagger}$	^{††}		_	tt	16,827	0.1	6	(4–	9)
Near drowning/																		
submersion	8,018	0.0	6	(3-	9)	2,275**	$0.0^{\dagger\dagger}$	^{††}		_	tt	10,293	0.0	4	(2-	6)
Other specified	232,279	1.3	173	(141–	205)	169,729	1.3	121	(96–	146)	402,008	1.3	146	(119–	173)
Unknown/																		
unspecified	534,055	3.0	398	(290-	505)	221,704	1.7	158	(118–	197)	756,251	2.5	275	(204–	346)
Total	16,350,316	93.2	12,171	(10	,666-1	3,676)	12,417,190	94.0	8,839	(7.814-	9,865)	28,773,094	93.6	10,470	(9	,230- 1	11,710)

Nonfatal

35)

721)

575)

63)

26)

27)

34)

7)

751)

73)

27)

10)

108)

869)

30)

7	
>	
2	
<	
₹	
Ñ	

TOTAL	17,537,152	100.0	13,054	(11,453-14,656)	13,203,419	100.0	9,399	(8,321– 10,477)	30,746,586	100.0	11,188	(9,875– 12,50	1)
				and injuries in whic									
				nt events; self harm			and confi	rmed intentionally	self-inflicted ir	ıjuries;	legal inte	rvention includ	tes
injuries inflict	ted by police (or other	r legal au	thorities while actir	ng in the line o	f duty.							

[§] Per 100,000 population.

VIOLENCE-RELATED

Sexual assault

Other assault Struck

by/against

Other bite/sting

Firearm gunshot

Other specified

unspecified

Other specified

unspecified

Legal intervention

Cut/pierce

Unknown/

Total

Total

Total

Self harm Poisoning

Cut/pierce

Unknown/

Assault

[†] Percentages may not total 100% because of rounding.

10,683

1,027,264

803,334

93,975

30,221

41,499

47,916

10,319

57,065

28,845

13,129

99,467

49,422

1,186,836

428^{††}

1,037,947

0.1

5.9

4.6

0.5

0.2

0.2

0.3

0.1

5.9

0.3

0.2

0.1

0.0

0.6

0.3

6.8

8

765

598

70

22

31

36

8

773

42

21

10

___††

37

74 (

883 (

12)

933)

718)

99)

31)

49)

44)

11)

943)

57)

30)

13)

97)

50)

4– 596-

478-

41-

14-

12-

27-

4-

602-

28-

13-

6-

51-

24-

697- 1069)

53,797

593,598

503,887

26,414

24,987

30,896

647,396

92,833

25,385

126,110

12,723

786,228

7,464

428**

4,133††

3.281**

0.4

4.5

3.8

0.2

0.2

 $0.0^{††}$

0.2

0.0

4.9

0.7

0.2

0.1

0.0

1.0

0.1

6.0

38

423

359

19

18

___††

22

___++

461

66

18

___††

90

9

560

5

20-

322-

275-

9-

12-

17-

349-

42-

11-

60-

5-

440-

2-

57)

523)

443)

29)

23)

27)

572)

90)

25)

8)

120)

680)

13)

64,480

1,621,290

1,307,649

120,388

55,209

45,632

78,812

13,600

1,685,770

149,898

54,231

20,593

225,577

62,145

1,973,492

855**

0.2

5.3

4.3

0.4

0.2

0.1

0.3

0.0

5.5

0.5

0.2

0.1

0.0

0.7

0.2

6.4

23

590

476

44

20

17

29

5

613

55

20

___††

82

23

718 (

7

12-

459-

377-

25-

14-

7–

23-

3-

476-

36-

13-

56-

15-

568-

5-

[¶] Confidence interval.


^{**}Includes weighted data for persons of unknown sex.

¹¹ National estimate might be unstable because it is based on <20 cases or the coefficient of variation is >30%.

Nonfatal Injuries — Continued

- 9. Quinlan KP, Thompson MP, Annest JL, et al. Expanding the National Electronic Injury Surveillance System to monitor all nonfatal injuries treated in US hospital emergency departments. Annals Emerg Med 1999;34:637–45.
- 10. Gotsch KE, Annest JL, Mercy JA, Ryan GW. Surveillance for fatal and nonfatal firearm-related injuries—United States, 1993–1998. In: CDC surveillance summaries (March). MMWR 2001;50(no. SS-2).

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending April 28, 2001, with historical data



^{*} No rubella cases were reported for the current 4-week period yielding a ratio for week 16 of

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending April 28, 2001 (17th Week)

	Cum. 2001		Cum. 2001
Anthrax Brucellosis* Cholera Cyclosporiasis* Diphtheria Ehrlichiosis: human granulocytic (HGE)* human monocytic (HME)*	- 18 - - 33 - 27 3	Poliomyelitis, paralytic Psittacosis* Qfever* Rabies, human Rocky Mountain spotted fever (RMSF) Rubella, congenital syndrome Streptococcal disease, invasive, group A	- 4 4 - 39 - 1,290
Encephalitis: California serogroup viral* eastern equine* St. Louis* western equine*	-	Streptococcal toxic-shock syndrome* Syphilis, congenital* Tetanus Toxic-shock syndrome	20 17 5 45
Hansen disease (leprosy)* Hantavirus pulmonary syndrome*† Hemolytic uremic syndrome, postdiarrheal* HIV infection, pediatric** Plague	23 3 19 72	Trichinosis Tularemia* Typhoid fever Yellow fever	5 9 56

[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

^{-:} No reported cases. *Not notifiable in all states.

[†]Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP). Last update April 24, 2001.

†Updated from reports to the Division of STD Prevention, NCHSTP.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending April 28, 2001, and April 29, 2000 (17th Week)

			OFF	diat	C		NET		<i>coli</i> O157:H7 PH	
	Cum.	Cum.	Chlan Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area UNITED STATES	2001 [§] 11,921	2000 12,725	2001 197,475	2000 219,929	2001 445	2000 457	2001 320	2000 466	2001 209	2000 375
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	469 14 13 10 271 40	789 14 11 1 526 33 204	7,528 393 359 194 3,328 945 2,309	7,568 398 352 189 3,274 770 2,585	18 2 - 6 5 3	27 4 1 8 7 2 5	38 5 7 2 17 1 6	42 3 4 1 20 -	32 4 6 - 15 2 5	44 3 4 2 16
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	2,254 97 1,028 635 494	3,159 157 1,930 628 444	16,811 N 8,970 1,374 6,467	21,105 N 8,968 4,318 7,819	46 21 23 1 1	92 24 63 1 4	31 24 - 7 N	63 56 4 3 N	15 10 1 4	56 38 2 7 9
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	926 167 85 433 189 52	1,259 172 97 803 141 46	27,689 2,898 4,873 7,366 9,675 2,877	38,276 10,074 4,226 10,602 7,981 5,393	137 35 17 - 36 49	95 17 5 15 12 46	66 22 12 9 14 9	88 17 10 29 12 20	26 10 2 7 - 7	29 9 10 - 5 5
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	243 47 24 117 1 - 16 38	271 47 23 123 - 3 19 56	10,034 1,906 1,325 3,195 323 611 778 1,896	12,412 2,665 1,406 4,241 308 583 1,167 2,042	21 - 11 5 - 2 3	25 4 6 1 3 2 3	26 8 4 5 - 3 - 6	67 10 13 25 2 2 10 5	24 12 2 6 1 1 -	68 30 7 16 4 2 6 3
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	3,720 72 436 297 270 28 190 250 392 1,785	3,357 63 388 264 237 19 169 256 355 1,606	42,100 987 4,043 1,206 5,544 755 6,923 4,130 8,214 10,298	40,349 989 3,919 1,062 4,951 682 6,635 3,523 8,027 10,561	98 1 20 7 6 - 14 - 30 20	59 1 4 - 3 - 6 - 32 13	39 - 2 - 6 1 20 2 2 6	38 1 6 - 8 2 8 2 8 2 8	20 - - U 5 - 9 2 2 2	32 - 1 U 9 2 2 1 8 9
E.S. CENTRAL Ky. Tenn. Ala. Miss.	682 121 220 174 167	596 80 259 163 94	15,410 2,832 4,756 4,183 3,639	16,387 2,563 4,665 5,234 3,925	12 1 2 4 5	15 - 2 7 6	13 1 7 5	27 10 10 1 1 6	8 2 5 - 1	21 8 11 - 2
W.S. CENTRAL Ark. La. Okla. Tex.	1,296 81 331 67 817	1,097 68 213 67 749	31,021 2,639 5,624 3,205 19,553	32,949 1,901 6,027 2,930 22,091	7 2 3 2	20 1 2 1 16	21 1 - 7 13	29 4 2 4 19	23 9 6 8	42 3 8 3 28
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	510 11 7 1 109 40 202 48 92	444 6 9 2 101 50 141 48 87	10,047 650 554 260 912 1,571 4,153 318 1,629	12,905 543 632 257 3,675 1,598 4,140 820 1,240	39 3 5 - 13 8 1 9	28 1 3 3 8 1 3 7 2	38 3 5 1 17 2 6 3	38 8 4 3 14 1 6 1	22 - - 12 - 5 4 1	25 - 3 2 7 2 8 1 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,821 201 69 1,526 9 16	1,753 196 47 1,456 5 49	36,835 4,484 481 29,998 799 1,073	37,978 4,261 2,287 29,726 826 878	67 N 2 65	96 U 2 94 -	48 11 6 27 - 4	74 12 12 43 1 6	39 8 6 23 - 2	58 25 13 14 1 5
Guam P.R. V.I. Amer. Samoa C.N.M.I.	9 408 2 - -	13 284 18 - -	1,628 53 U U	U U	- - - U U	- - U U	N - - U U	N 1 - U U	U U U U U	U U U U

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.

*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

† Chlamydia refers to genital infections caused by *C. trachomatis*. Totals reported to the Division of STD Prevention, NCHSTP.

§ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update April 24, 2001.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending April 28, 2001, and April 29, 2000 (17th Week)

		ding April	Hepati	tis C;			l I	Lyı	
	Gono Cum.	rrhea Cum.	Non-A,	Non-B Cum.	Legionel Cum.	llosis Cum.	Listeriosis Cum.	Dise Cum.	Cum.
Reporting Area UNITED STATES	2001 93,865	2000	2001 688	2000	2001 205	2000	2001 111	2001 641	2000
NEW ENGLAND	2,038	109,895 2,107	12	1,074 6	205 10	2 18 16	111	164	1,333 185
Maine N.H.	43 40	25 28	-	-	3	2 2	-	42	18
Vt. Mass.	28 1,020	17 836	5 7	3 3	3	- 9	- 7	1 38	1 76
R.I. Conn.	245 662	201 1,000	-	-	1	3	, - 4	83	90
MID. ATLANTIC	10,142	11,700	24	226	20	50	20	296	902
Upstate N.Y. N.Y. City	2,350 3,811	1,982 3,733	15 -	17 -	13 3	18 6	9 3	234	352 37
N.J. Pa.	829 3,152	2,431 3,554	9	197 12	3 1	2 24	5 3	- 62	101 412
E.N. CENTRAL	15,169	22,840	73	87	57	63	11	17	42
Ohio Ind.	2,150 2,030	5,574 1,931	5 -	2	32 5	27 9	3 1	17 -	5 -
III. Mich.	4,512 5,554	7,457 5,546	3 65	9 76	14	7 11	6	-	2
Wis.	923	2,332 5,222	- 169	- 170	6	9 11	1 2	U 22	35 24
W.N. CENTRAL Minn.	4,079 556	1,026	-	170	18 1	1	-	15	11
lowa Mo.	349 2,008	314 2,555	164	162	5 9	3 5	1	1 4	7
N. Dak. S. Dak.	11 71	16 83	-	-	-	1	-	-	-
Nebr. Kans.	248 836	402 826	2 3	2 5	2 1	1	1	1 1	1 5
S. ATLANTIC Del.	26,254 528	28,738 540	34	24 2	29	41 4	20	112	141 23
Md. D.C.	2,415 1,046	2,763 727	11	4	6 1	10	2	93 7	94
Va. W. Va.	2,918 165	3,454 195	- 4	1	4 N	3 N	3	7 1	12 4
N.C. S.C.	5,832 3,042	5,756 3,033	7 2	8	3	5 2	- 1	3	4
Ga.	4,572	4,975	- 10	- - 6	2 12	2 15	5 7	- - 1	- -
Fla. E.S. CENTRAL	5,736 9,890	7,295 11,456	72	161	20	6	7	2	4 1
Ky. Tenn.	1,091 3,112	1,041 3,533	3 21	15 31	6 8	4 1	1 3	2	1
Ala. Miss.	3,396 2,291	3,916 2,966	1 47	4 111	4 2	1	3	-	-
W.S. CENTRAL	15,113	16,859	144	310	3	5	2	1	13
Ark. La.	1,654 3,805	920 4,226	3 58	3 199	2	2	1 -	1	- 1
Okla. Tex.	1,505 8,149	1,277 10,436	2 81	1 107	1 -	1 2	- 1	-	12
MOUNTAIN Mont.	3,167 <i>3</i> 5	3,297 10	126	32 1	17	13	11	3	1
Idaho	27 17	30	1	-	- - 1	1	-	1	-
Wyo. Colo. N. Mex.	1,069	23 1,012	101 9 8	13	6	6	1	-	-
Ariz.	274 1,098	334 1,355	8 4	4 10	1	1 2	3 2	-	-
Utah Nev.	33 614	97 436	3	3	1 2	3	1 4	1	-
PACIFIC Wash.	8,013 1,005	7,676 763	34 9	58 8	31 6	13 6	27 2	24 2	24
Oreg. Calif.	73 6,648	287 6,406	9 2 23	12 38	N 25	Ň 7	1 24	1 21	3 21
Alaska Hawaii	100 187	95 125	-	-	-	-	-	- N	- N
Guam	-	-	-	-	-	-	-	-	-
P.R. V.I.	578 6	159 	-	1 . .	2	-	-	N -	N -
Amer. Samoa C.N.M.I.	U U	U U	U U	U U	U U	U U	-	U U	U U

N: Not notifiable.

U: Unavailable.

-: No reported cases.

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending April 28, 2001, and April 29, 2000 (17th Week)

	Weeks	namy Ap	111 20, 20	o i, alia A		Salmor	nellosis*	
	Mal	laria	Rabies	s, Animal	NE	TSS		ILIS
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000
UNITED STATES	252	304	1,525	1,895	6,807	8,213	5,245	7,631
NEW ENGLAND Maine N.H.	23 2 2	10 1 -	180 26 5	209 51 3	548 73 42	502 38 25	483 36 34	537 25 37
Vt. Mass.	6	1 6	28 51	15 65	24 314	37 295	23 252	44 291
R.I. Conn.	1 12	2	21 49	18 57	26 69	18 89	35 103	37 103
MID. ATLANTIC Upstate N.Y.	43 11	59 17	231 178	305 213	599 230	1,203 261	798 122	1,400 358
N.Y. City	21	27	3	3	219	359	291	383
N.J. Pa.	8 3	6 9	49 1	47 42	107 43	317 266	143 242	263 396
E.N. CENTRAL Ohio	27 5	39 3	9 1	15 2	1,008 392	1,223 272	749 274	695 246
Ind.	8	2	1	-	93	123	75	144
III. Mich. Wis.	14	23 9 2	1	7 6	229 192 102	425 198 205	179 143 <i>7</i> 8	1 218 86
W.N. CENTRAL	7	18	101	169	382	412	427	548
Minn. Iowa	1 1	4 1	15 17	24 23	71 73	38 53	156 60	164 55
Mo.	2	2	6 17	7	118	145	146	180
N. Dak. S. Dak.	-	2	17	39 40	1 27	14 21	12 12	21 29
Nebr. Kans.	1 2	3 6	33	36	32 60	62 79	- 41	41 58
S. ATLANTIC Del.	68 1	67 2	656 12	655 10	1,795 24	1,330 22	1,106 23	1,153 32
Md.	29	27	92	137	188	191	170	206
D.C. Va.	4 13	- 17	126	159	23 307	- 165	U 217	U 171
W. Va. N.C.	- 1	- 7	46 189	38 162	16 325	38 207	18 175	29 170
S.C.	3 3	- 1	40 77	43 67	216	118	208 249	95
Ga. Fla.	14	13	74	39	237 459	216 373	46	339 111
E.S. CENTRAL Ky.	8 2	11 2	59 7	64 9	401 <i>7</i> 3	411 83	177 36	319 58
Ténn. Ala.	3 3	2 6	43 9	40 15	112 155	101 129	98 31	139 104
Miss.	-	1	-	-	61	98	12	18
W.S. CENTRAL Ark.	4 1	4 1	89	335	501 <i>7</i> 9	863 78	401 29	522 50
La. Okla.	1 1	3	30	23	89 41	146 <i>7</i> 7	135 39	98 66
Tex.	1	-	59	312	292	562	198	308
MOUNTAIN Mont.	19 2	16 1	81 13	58 16	533 19	745 23	406	664
Idaho Wvo.	2	-	16	22	21 25	40 15	4 13	38 14
Cólo. N. Mex.	9 1	8	2	3	158 6 2	240 63	138 48	212 52
Ariz.	1	2	50	16	160	195	127	183
Utah Nev.	2 2	3 2	-	1 -	57 31	110 59	53 23	108 57
PACIFIC Wash.	53 2 3	80 4	119 -	85 -	1,040 107	1,524 98	698 144	1,793 185
Oreg. Calif.	3 45	18 56	- 87	- 75	28 796	101 1,250	71 401	130 1,406
Alaska Hawaii	45 1 2	- 2	32	10	796 14 95	1,250 19 56	401 - 82	1,400 18 54
Guam	-	_	-	-	-	-	U	U
P.R. V.I.	-	2	49 -	18 -	83	95 -	U U	Ú U
Amer. Samoa C.N.M.I.	U U	U U	U U	U U	U U	U U	U U	Ú Ú

N: Not notifiable. U: Unavailable. -: No reported cases.

* Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending April 28, 2001, and April 29, 2000 (17th Week)

	<u>weeks er</u>			01, and A	<u>pril 29, 2</u>	<u>000 (17th</u>	Week)	
	NET	Shige		PHLIS		rphilis & Secondary)	Tuba	rculosis
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2001	2000	2001	2000	2001	2000	2001	2000
UNITED STATES	3,263	5,246	1,594	3,169	1,623	2,081	3,010	3,729
NEW ENGLAND Maine	51 1	101 2	56 1	86 -	13 -	24 -	101 5	77 3
N.H. Vt.	1 2	1 1	1 1	4	-	-	6 1	2 1
Mass.	35	71	35	54	9	20	57	64
R.I. Conn.	4 8	7 19	5 13	9 19	1 3	1 3	10 22	7 -
MID. ATLANTIC	301	809	245	562	115	96	630	637
Upstate N.Y. N.Y. City	129 102	276 412	6 125	135 282	4 79	4 45	<i>7</i> 5 338	68 374
N.J. Pa.	40 30	69 52	49 65	70 75	14 18	18 2 9	149 68	159 36
E.N. CENTRAL	498	883	246	294	245	438	316	386
Ohio	153	58	73	43	27	23	47	80
Ind. III.	83 129	124 331	16 84	24 2	55 63	155 151	27 167	29 215
Mich. Wis.	108 25	263 107	66 7	216 9	92 8	88 21	51 24	33 29
W.N. CENTRAL	348	331	308	269	16	31	135	166
Minn. Iowa	105 <i>7</i> 4	43 61	173 64	83 64	7 -	3 8	71 9	54 13
Mo. N. Dak.	79 9	181 1	55 1	99 1	6	15 -	37	63
S. Dak.	26	1	1	-	-	-	4	8
Nebr. Kans.	24 31	22 22	14	11 11	3	2 3	14 -	6 22
S. ATLANTIC	541	591	163	173	647	679	552	603
Del. Md.	4 38	4 33	3 13	4 10	2 78	2 107	- 57	2 72
D.C. Va.	19 38	33	U 19	U 26	13 48	18 43	15 58	- 71
W. Va. N.C.	4 130	2 37	6 54	2 18	157	1 180	9 79	14 98
S.C.	33	9	20	10	93	70	24	26
Ga. Fla.	68 207	66 407	44 4	65 38	83 173	120 138	121 189	156 164
E.S. CENTRAL	299	234	76 20	178	185	312	199	252
Ky. Tenn.	106 33	47 118	30 23	28 138	15 106	32 198	32 43	27 93
Ala. Miss.	82 78	12 57	17 6	9 3	30 34	42 40	91 33	87 45
W.S. CENTRAL	474	831	257	260	227	295	359	626
Ark. La.	182 27	66 94	65 58	22 42	15 50	33 69	45	48 46
Okla. Tex.	6 259	11 660	2 132	8 188	29 133	56 137	39 275	32 500
MOUNTAIN	217	311	140	187	59	67	273 84	146
Mont. Idaho	7	2 26	-	17	-	-	4	4 2
Wyo.	-	1	-	2	-	1	-	-
Colo. N. Mex.	49 40	52 32	38 28 53	27 18	4 4	3 6	26 5 25 5	18 19
Ariz. Utah	92 13	119 21	53 13	56 28	42 6	55	25 5	57 8
Nev.	16	58	8	39	3	2	19	38
PACIFIC Wash.	534 56	1,155 208	103 62	1,160 241	116 21	139 20	634 55	836 63
Oreg. Calif.	8 455	89 840	30	52 856	1 91	3 116	512	22 689
Alaska	2	6	-	3	-	-	14	25
Hawaii Guam	13	12	11 U	8 U	3	-	53	37
P.R.	7	14	U	U	115	59	38	50
V.I. Amer. Samoa	Ü	Ü	U U	U	Ü	Ü	Ü	Ü
C.N.M.I.	U	U	U	U	U	U	U	U

N: Not notifiable. U: Unavailable. -: No reported cases.

*Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending April 28, 2001, and April 29, 2000 (17th Week)

	<i>,,</i>		1		29, 200		1 wee	; K /	N/1	loo (Db.c.	ula)	
		<i>ienzae,</i> isive	A	epatitis (Vi	rai), By Tyl	pe	Indige	nous	Impo	les (Rubed rted*	Tota	l I
Reporting Area	Cum. 2001 [†]	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	2001	Cum. 2001	2001	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	493	457	2,842	4,106	1,881	1,947	<u> 2001 </u> -	2001	-	16	36	25 25
NEW ENGLAND Maine N.H.	16 1 -	37 1 6	136 3 5	104 6 8	31 3 7	33 2 6	-	3	- - -	1 - -	4 - -	- - -
Vt. Mass. R.I. Conn.	- 15 - -	3 21 1 5	2 42 6 78	3 42 6 39	1 2 6 12	3 1 6 15	- - -	1 2 -	- - -	1 - -	1 3 - -	- - -
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	58 22 21 14 1	67 27 23 13 4	246 79 106 46 15	288 77 151 - 60	253 43 147 44 19	326 36 184 14 92	- - - -	1 - - 1	- - - -	5 4 - 1	6 4 - 1 1	8 - 8 -
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	59 27 16 9 3 4	75 24 8 28 4 11	326 90 29 87 115 5	585 115 15 228 176 51	235 42 6 20 167	223 36 15 27 136 9	- - - - -	- - - -	- - - - -	7 2 2 3 -	7 2 2 3	3 2 - - 1
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak.	19 8 1 8 -	15 7 - 7 1	143 9 15 42 - 1	288 36 32 162	63 7 7 35 - 1	82 7 14 42 -	- - - -	4 2 - 2	-	- - - -	4 2 - 2 -	-
Nebr. Kans.	2	-	18 58	13 45	6 7	14 5	Ū -	-	Ü	-	-	- -
S. ATLANTIC Del. Md. D.C.	166 - 43	110 - 28	598 - 87 15	414 6 49	420 - 51 3	320 4 45	-	3 - 2	-	1 - 1	4 - 3	-
Va. W. Va. N.C. S.C. Ga. Fla.	9 4 22 4 40 44	21 3 8 5 31 14	45 2 38 21 214 176	50 34 77 14 52 132	43 7 85 5 108 118	50 2 92 2 45 80	- - - -	- - - 1	-	- - - -	- - - 1	-
E.S. CENTRAL Ky. Tenn. Ala. Miss.	33 1 14 17 1	19 9 7 3	96 12 44 36 4	180 19 60 23 78	110 14 41 34 21	144 28 62 11 43	- - - -	- - - -	- - - -	- - - -	- - - -	-
W.S. CENTRAL Ark. La. Okla. Tex.	15 2 13	27 10 17	369 18 31 56 264	781 59 31 117 574	222 32 15 25 150	215 31 54 30 100	- - - -	1 - - 1	- - - -	- - - -	1 - - - 1	- - - -
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex.	85 1 4 18 12	53 2 - 11 11	288 4 27 15 31 8	302 1 12 3 59 33	195 1 4 16 40 44	160 3 4 - 32 51	- - - -	- - - - -	- - - - -	1 - 1 - -	1 - 1 - -	8 - - 3 -
Ariz. Utah Nev.	40 3 7	23 4 2	146 24 33	153 18 23	66 9 15	52 4 14	-	- - -	-	- - -	- - -	3 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	42 1 3 23 1 14	54 3 16 20 1 14	640 24 20 584 11	1,164 93 81 979 4 7	352 31 10 300 4 7	444 17 35 384 2 6	- - - -	8 - 1 7 - -	-	1 - - 1 - -	9 - 1 8 - -	6 3 - 3 -
Guam P.R. V.I. Amer. Samoa	- - - U	- 2 - U	33 - U	113 - U	- 18 - U	- 80 - U	- U U	- - - U	- U U	- - - U	- - - U	- - - U
C.N.M.I.	ŭ	ŭ	ŭ	ŭ	ŭ	ŭ	ŭ	ŭ	ŭ	ŭ	ŭ	Ŭ

N: Not notifiable. U: Unavailable. -: No reported cases.
*For imported measles, cases include only those resulting from importation from other countries.
† Of 107 cases among children aged <5 years, serotype was reported for 52, and of those, eight were type b.

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending April 28, 2001, and April 29, 2000 (17th Week)

and April 29, 2000 (17th Week)													
		jococcal ease		Mumps			Pertussis		Rubella				
Reporting Area	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000		
UNITED STATES	936	889	4	58	149	45	1,535	1,688	1	4	37		
NEW ENGLAND	62	52	-	-	2	-	224	436	-	-	6		
Maine N.H.	1 5	3 3	-	-	-	-	16	9 52	-	-	- 1		
Vt. Mass.	4 36	2 34	-	-	-	-	22 178	82 272	-	-	- 4		
R.I.	1	3	-	-	1	-	1	6	-	-	-		
Conn.	15	7	-	-	1	-	7	15	-	-	1		
MID. ATLANTIC Upstate N.Y.	71 29	84 17	-	1 -	11 5	1 1	90 74	158 72	-	1 1	6 2		
N.Y. City N.J.	18 22	24 20	-	1	3	-	6 2	31	-	-	4		
Pa.	2	23	-	-	3	-	8	55	-	-	-		
E.N. CENTRAL	112	155	1	7	19	8	174	219	-	1	-		
Ohio Ind.	43 14	27 18	- 1	1 1	6 -	4 4	116 11	131 12	-	-	-		
III.	20 23	44 49	-	5	4 8	-	14 15	19 14	-	1	-		
Mich. Wis.	23 12	49 17	-	-	1	-	18	43	-	-	-		
W.N. CENTRAL	62	53	-	5	7	-	74	58	1	1	1		
Minn. Iowa	7 16	3 12	-	1 -	4	-	17 9	31 8	1	- 1	-		
Mo. N. Dak.	23 3	28 1	-	-	1	-	33	8 1	-	-	-		
S. Dak.	2	4	-	-	-	-	3	1	-	-	-		
Nebr. Kans.	2 9	3 2	U -	4	1 1	U -	2 10	2 7	U -	-	1 -		
S. ATLANTIC	179	128	-	6	19	5	71	116	-	1	9		
Del. Md.	24	12	-	3	- 5	-	- 11	1 35	-	-	-		
D.C.	-	-	-	-	-	-	1	-	-	-	-		
Va. W. Va.	20 4	23 3	-	2	4	-	8 1	10	-	-	-		
N.C. S.C.	40 18	24 10	-	- 1	3 6	1 1	25 14	29 15	-	-	6 2		
Ga.	24	22 34	-	-	-	-	2	13	-	1	-		
Fla. E.S. CENTRAL	49 67	34 57	- 1	- 1	1 4	3 3	9 37	13 39	-	-	1 4		
Ky.	13	12	1	1	-	1	11	25	-	-	1		
Tenn. Ala.	23 27	24 16	-	-	2 1	2	16 7	5 8	-	-	3		
Miss.	4	5	-	-	1	-	3	1	-	-	-		
W.S. CENTRAL Ark.	139 10	102 5	-	6 1	15 1	7	33 3	60 6	-	-	4		
La.	46	32	-	2	3	-	1	4	-	-	1		
Okla. Tex.	14 69	17 48	-	3	11	7	1 28	50	-	-	3		
MOUNTAIN	51	52	1	6	9	20	713	287	-	-	-		
Mont. Idaho	4	1 6	-	-	1 -	- 1	5 160	6 35	-	-	-		
Wyo. Colo.	1	-	-	1	-	-	1	-	-	-	-		
N. Mex.	20 8 9	14 7	-	2 2	1 1	-	135 42	173 41	-	-	-		
Ariz. Utah	9 5	16 6	-	-	- 4	17 2	354 11	23 6	-	-	-		
Nev.	4	2	1	1	2	-	5	3	-	-	-		
PACIFIC Week	193	206	1	26	63	1	119	315	-	-	7		
Wash. Oreg.	34 12	15 25	N	N	1 N	1 -	30 6	89 26	-	-	6 -		
Calif. Alaska	139 1	158 3 5	1	17 1	55 2	-	75 -	178 4	-	-	1		
Hawaii	7	5	-	8	5	-	8	18	-	-	-		
Guam	- 1	-	-	-	-	-	-	-	-	-	-		
P.R. V.I.	-	4	Ū	-		Ū		-	Ū	-	-		
Amer. Samoa C.N.M.I.	U U	U U	U U	U U	U U	U	U U	U U	U	U U	U U		

N: Not notifiable.

U: Unavailable.

-: No reported cases.

TABLE IV. Deaths in 122 U.S. cities,* week ending April 28, 2001 (17th Week)

April 28, 2001 (17th Week)															
	All Causes, By Age (Years)								All Causes, By Age (Years)						P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conn Providence, R.I. Somerville, Mass. Springfield, Mass Waterbury, Conn.	. 22 27 86 24 22 ss. 33 . 43 U 9	414 100 34 19 21 54 18 31 34 U 7 23 24	94 21 10 3 4 20 5 4 1 6 U 1 3 2	43 10 3 - 2 10 1 - 1 3 U 1 4 2	5 3 - - 1 - - - - -	11 6 - - 1 - - - U	წნთ 4 თთ 5 თ მ თ მ დ	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, F Tampa, Fla. Washington, D.C Wilmington, Del	109 52 63 54 Fla. 61 202 C. 199 l. 18	887 125 88 65 121 52 34 35 37 47 144 128	290 47 38 20 38 13 11 12 10 10 38 46 7	132 25 20 10 9 20 2 10 4 3 10	64 16 2 6 4 13 4 5 1 7 5	41 6 3 5 8 11 1 2 - 3 1	87 13 6 12 9 1 11 5 6 17
Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§ Jersey City, N.J. New York City, N.Y. Newark, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	52 2,253 60 19 89 35 57 43 7. 1,241 U 30 258 58 30 141	31 1,577 40 16 67 81 24 42 34 848 101 17 23 60 13 12 10 10 10 10 10 10 10 10 10 10 10 10 10	14 438 12 1 14 8 8 10 6 262 0 7 47 11 1 25 1 3 13 5 4 4 U	151 3 2 6 4 2 2 91 U 4 23 - 1 1 1 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1	1 42 1 - - 2 1 19 U 1 9 1 - 6 1 - - - - - - - - - - - - - - - -	44 4 2 1 1 1 20 0 8 1 - 5	5 120 7 2 9 1 - 4 - 50 10 10 10 10 10 10 10 10 10	E.S. CENTRAL Birmingham, Ala Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, A Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, T Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla.	91 91 93 94 95 95 95 95 95 95 95 95 95 95 95 95 95	535 116 56 63 130 71 42 U 1,043 53 58 143 226 48 31 122 39 92	136 28 13 20 13 52 5 5 0 334 14 25 10 43 22 33 77 20 22 35 10 22 35 20 21 30 22 31 43 25 10 25 25 10 2 25 25 10 25 25 25 25 25 25 25 25 25 25 25 25 25	57 9 3 11 5 14 13 2 1 13 9 7 3 24 3 11 34 3 10	15 4 · 2 · 7 1 1 U 63 3 5 3 3 6 1 8 8 26 2 6 3 · ·	13 4 2 2 2 2 2 1 U 31 2 2 3 10 2 2 1	69 18 5 7 7 18 7 7 U 110 4 3 10 18 4 3 28 5 11 14 4 6
E.N. CENTRAL Akron, Ohio Canton, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, Mi Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansas City, Mo. Lincoln, Nebr. Minneapolis, Min Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	180 43 117 54 43 61 U 725 55 45 . 31 . 37	1,137 48 41 170 75 156 84 108 40 53 9 45 130 45 130 45 20 20 22 25 12 60 49 66 45	312 11 17 32 32 45 8 6 37 34 8 32 11 12 12 10 10 10 11 12 10 10 10 10 10 10 10 10 10 10 10 10 10	87 - 2U 7 15 13 7 9 2 5 1 2 6 1 6 5 2 1 U 3 8 3 1 3 6 2 6 4 4 3 6	33 - U 7 3 5 1 4 - 2 - 1 1 6 1 1 2 U - 1 7 2 - 1 4 1 1 - 3 2 3	36 1 U 9 4 4 6 4 2 2 1 1 2 U 1 1 5 1 5 1 2 3 3 4	111 24U631439210 · 4104442 · 3U1 528328185 · 116	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cal Los Angeles, Cal Pasadena, Calif. Portland, Oreg. Sacramento, Cal San Diego, Calif San Francisco, C San Jose, Calif. Santa Cruz, Calif. Seattle, Wash. Spokane, Wash. Tacoma, Wash. TOTAL	42 olo. 47 111 214 35 170 27 tah 110 143 1,325 19 120 ii 62 if. 82 if. 196 160 iif. 178 alif. U 202 f. 29 130	714 81 29 33 74 158 26 110 20 7 7 106 950 13 85 53 121 127 119 U 148 21 119 44 60 7,784	167 12 8 8 20 34 6 33 3 18 25 246 5 22 U 8 25 342 20 34 7 36 10 16 2,143	76 4 15 10 16 2 16 3 8 11 81 1 9 10 10 10 10 11 11 4 3 7 795	26 3 3 1 2 2 5 1 6 1 4 - 25 - 2 U 2 3 3 U - 4 5 2 U 4 - 1 - 2 2 2 9 0	17 1 1 5 5 1 20 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	80 11 3 9 9 10 5 10 5 9 9 10 3 4 4 3 8 0 10 17 14 14 16 6 8 5 6 8 5 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8

U: Unavailable. -:No reported cases.

*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

¹Pneumonia and influenza.

^{*}Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

*Total includes unknown ages.

Contributors to the Production of the MMWR (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Carol A. Worsham

CDC Operations Team

Carol M. Knowles

Deborah A. Adams Willie J. Anderson Patsy A. Hall Mechele Hester Felicia J. Perry Pearl Sharp

Informatics

T. Demetri Vacalis, Ph.D.

Michele D. Renshaw Erica R. Shaver The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the MMWR Series, including material to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Epidemiology Program Office Writers-Editors, MMWR (Weekly) Director, Centers for Disease Control and Prevention Jill Crane Jeffrey P. Koplan, M.D., M.P.H. Stephen B. Thacker, M.D., M.Sc. David C. Johnson Deputy Director for Science and Editor, MMWR Series Desktop Publishing Public Health, Centers for Disease John W. Ward, M.D. Control and Prevention Lynda G. Cupell Acting Managing Editor, MMWR David W. Fleming, M.D. Morie M. Higgins (Weekly) Teresa F. Rutledge

☆U.S. Government Printing Office: 2001-633-173/48228 Region IV